Kentucky Trust Co Buys New Position in Sanofi (NASDAQ:SNY)

Kentucky Trust Co bought a new stake in shares of Sanofi (NASDAQ:SNY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 9,045 shares of the company’s stock, valued at approximately $436,000.

A number of other hedge funds also recently modified their holdings of SNY. Jennison Associates LLC lifted its position in shares of Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after acquiring an additional 1,424,289 shares during the period. DAVENPORT & Co LLC lifted its position in shares of Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after buying an additional 664,455 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after buying an additional 395,744 shares during the period. Institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Trading Up 1.2 %

SNY stock opened at $53.90 on Wednesday. The business has a fifty day moving average price of $49.94 and a 200 day moving average price of $52.40. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a market capitalization of $136.79 billion, a price-to-earnings ratio of 21.65, a P/E/G ratio of 0.99 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. Analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.